Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 9, 2010, Pages 2318-2329

  Lin, A ^a   Zhu, C C ^a   Chen, H X ^a   Chen, B F ^a   Zhang, X ^a   Zhang, J G ^a   Wang, Q ^a   Zhou, W J ^a   Hu, W ^a   Yang, H H ^a   Xu, H H ^a   Yan, W H ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

HLA G; Non small cell lung cancer; Prognosis

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; HLA-G ANTIGEN;

ARTICLE; BLOOD; CELL MEMBRANE; CYTOTOXICITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 78649416004     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00858.x     Document Type: Article

References (62)

1. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-8.
2. Gomes AQ, Correia DV, Silva-Santos B. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep. 2007; 8: 1024-30.
3. Carosella ED, Favier B, Rouas-Freiss N et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 2008; 111: 4862-70.
4. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA. 1992; 89: 3947-51.
5. Paul P, Cabestre FA, Ibrahim EC et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol. 2000; 61: 1138-49.
6. Rebmann V, Busemann A, Lindemann M et al. Detection of HLA-G5 secreting cells. Hum Immunol. 2003; 64: 1017-24.
7. Pistoia V, Morandi F, Wang X et al. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol. 2007; 17: 469-79.
8. Carosella ED, Moreau P, Lemaoult J et al. HLA-G: from biology to clinical benefits. Trends Immunol. 2008; 29: 125-32.
9. Kovats S, Main EK, Librach C et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990; 248: 220-3.
10. Crisa L, McMaster MT, Ishii JK et al. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med. 1997; 186: 289-98.
11. Le Discorde M, Moreau P, Sabatier P et al. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol. 2003; 64: 1039-44.
12. Ito T, Ito N, Saathoff M et al. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol. 2005; 125: 1139-48.
13. Cirulli V, Zalatan J, McMaster M et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes. 2006; 55: 1214-22.
14. Menier C, Rabreau M, Challier JC et al. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood. 2004; 104: 3153-60.
15. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008; 26: 212-22.
16. Paul P, Rouas-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA. 1998; 95: 4510-5.
17. Rouas-Freiss N, Moreau P, Ferrone S et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005; 65: 10139-44.
18. Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 2008; 68: 627-30.
19. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-62.
20. Torres MI, Le Discorde M, Lorite P et al. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int Immunol. 2004; 16: 579-83.
21. Carosella ED, Moreau P, Aractingi S et al. HLA-G: a shield against inflammatory aggression. Trends Immunol. 2001; 22: 553-5.
22. Leleu X, Le Friec G, Facon T et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005; 11: 7297-303.
23. Rebmann V, Regel J, Stolke D et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003; 13: 371-7.
24. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995; 75: 191-202.
25. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 1710-7.
26. Lin A, Yan WH, Xu HH et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol. 2007; 18: 1804-9.
27. Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol. 2008; 29: 313-21.
28. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997; 18: 89-95.
29. Romero P, Valmori D, Pittet MJ et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002; 188: 81-96.
30. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003; 90: 127-56.
31. Redondo M, Ruiz-Cabello F, Concha A et al. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res. 1991; 51: 2463-8.
32. Kikuchi E, Yamazaki K, Torigoe T et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007; 98: 1424-30.
33. Korkolopoulou P, Kaklamanis L, Pezzella F et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996; 73: 148-53.
34. Ramnath N, Tan D, Li Q et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother. 2006; 55: 891-9.
35. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol. 2004; 16: 644-50.
36. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 2006; 24: 178-86.
37. Amiot L, Le Friec G, Sebti Y et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol. 2003; 13: 379-85.
38. Ugurel S, Rebmann V, Ferrone S et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001; 92: 369-76.
39. Urosevic M, Kurrer MO, Kamarashev J et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001; 159: 817-24.
40. Yie SM, Yang H, Ye SR et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer. 2007; 58: 267-74.
41. Yie SM, Yang H, Ye SR et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007; 128: 1002-9.
42. Yie SM, Yang H, Ye SR et al. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol. 2007; 14: 2721-9.
43. Ye SR, Yang H, Li K et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007; 20: 375-83.
44. Hansel DE, Rahman A, Wilentz RE et al. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer. 2005; 35: 15-23.
45. Ishigami S, Natsugoe S, Miyazono F et al. HLA-G expression in gastric cancer. Anticancer Res. 2006; 26: 2467-72.
46. Rudstein-Svetlicky N, Loewenthal R, Horejsi V et al. HLA-G levels in serum and plasma. Tissue Antigens. 2007; 69: 140-2.
47. Chen XY, Yan WH, Lin A et al. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens. 2008; 72: 335-41.
48. Nasef A, Chapel A, Mazurier C et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007; 13: 217-26.
49. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol. 2003; 13: 337-42.
50. Morandi F, Levreri I, Bocca P et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007; 67: 6433-41.
51. Nückel H, Rebmann V, Dürig J et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005; 105: 1694-8.
52. Yan WH, Lin A, Chen BG et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med. 2008; 12: 889-98.
53. Gros F, Sebti Y, de Guibert S et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006; 8: 223-30.
54. Singer G, Rebmann V, Chen YC et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003; 9: 4460-4.
55. Rudstein-Svetlicky N, Loewenthal R, Horejsi V et al. HLA-G levels in serum and plasma. Tissue Antigens. 2006; 67: 111-6.
56. Fons P, Chabot S, Cartwright JE et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood. 2006; 108: 2608-15.
57. Rajagopalan S, Bryceson YT, Kuppusamy SP et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006; 4: e9.
58. Gros F, Cabillic F, Toutirais O et al. Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol. 2008; 38: 742-9.
59. Carosella ED, HoWangYin KY, Favier B et al. HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol. 2008; 69: 700-7.
60. Bukur J, Rebmann V, Grosse-Wilde H et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003; 63: 4107-11.
61. Naji A, Durrbach A, Carosella ED et al. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasLmediated pathways. Hum Immunol. 2007; 68: 233-9.
62. Komohara Y, Harada M, Ishihara Y et al. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep. 2007; 18: 1463-8.